What challenges does the epidemic bring to the pharmaceutical industry?

Guided reading

Guided reading

It has been more than two years since the new crown epidemic struck.

It has been more than two years since the new crown epidemic struck.

What impact has the epidemic had on the biopharmaceutical industry? Will the "new generation" such as antigen self-testing rise? How will the pharmaceutical industry develop in the future?

Recently, we have invited three senior industry experts, they are Professor Xu Yuhong, founder/CSO of Takata Biopharmaceutical Co.

Recently, we have invited three senior industry experts, they are Professor Xu Yuhong, founder/CSO of Takata Biopharmaceutical Co.

The purpose of this event is to explore how to deal with the crisis and the future development of biomedicine in the context of the current epidemic.

What impact has this round of epidemic brought to the pharmaceutical industry? Do you think the impact will be temporary or long-term? How to minimize the negative impact of the epidemic?

Zhang Yan: The most obvious impact of the epidemic is that many companies may not be able to operate normally.

As for whether the impact is short-term or long-term, I personally think it may last for at least the next one to two years

On April 19th, the Institute of Basic Medical Innovation of Zhejiang University and Deep Research Science jointly held the first live broadcast of the "Yuanchuang Forum" in Linping District.

Q: On the other hand, we have also seen the rapid development of nucleic acid testing, antigen testing, new crown vaccine research and development and surrounding industries due to the epidemic.

On the other hand, we have also seen the rapid development of nucleic acid testing, antigen testing, new crown vaccine research and development and surrounding industries due to the epidemic.

Zhang Yan: I still want to look at this issue with a positive attitude

Q: We know that the mRNA new crown vaccine is very hot recently.

We know that the mRNA new crown vaccine is very hot recently, and the mRNA vaccine delivery system made by Mr.

In fact, I hope that scientists can apply mRNA technology to develop more advanced and better drug products

Q: Regarding the impact of the new crown epidemic, what industry policies do you think relevant national departments need to stimulate the healthy development of this field? For example, how to speed up clinical approval, how to remedy the incomplete clinical data caused by the epidemic, and whether to increase capital investment in this field?

Regarding the impact of the new crown epidemic, what industry policies do you think relevant national departments need to stimulate the healthy development of this field? For example, how to speed up clinical approval, how to remedy the incomplete clinical data caused by the epidemic, and whether to increase capital investment in this field?

Zhang Yan: According to the development trend of the new crown virus, there will be policy support for pharmaceutical companies

But at the same time, there has always been some controversy in this regard.

But I believe that with the opportunity of the new crown, mRNA technology can enter the public's field of vision faster and be recognized by the public
.
With a lot of data to support, I believe that the entire mRNA industry will develop very well, and we also hope to see more applications of mRNA technology
.

Q: In the medium and long term, the logic of the long-term development and growth of the pharmaceutical industry will not change, because our country is still vigorously encouraging innovation and increasing the availability of drugs, but how to solve the current difficulties and challenges? What suggestions do teachers have?

In the medium and long term, the logic of the long-term development and growth of the pharmaceutical industry will not change, because our country is still vigorously encouraging innovation and increasing the availability of drugs, but how to solve the current difficulties and challenges, what suggestions do you have?

Zhao Wufeng: I think we may have to wait and see for a while
.
It depends on the development trend of the epidemic and possible changes in national policies
.
The bright spot, at least for now, is that existing vaccines do not allow complete immune escape from the new coronavirus, and they may become less virulent in the future
.
If this trend continues, then I think it may be possible to gradually consider letting go, and only after letting go can it return to a normal state
.

Xu Yuhong: Actually, I don't have such a high level.
I can only talk about some ideas from the perspective of a company, or from the perspective of a new drug researcher
.
There are definitely difficulties and challenges at the moment, and they are very wide in scope and time-consuming.
We can only hope that we can persevere in the difficult situation and recover slowly
.
I hope the industrial environment can return to normal as soon as possible, and I hope we still have enough energy to recover
.

Zhang Yan: The impact on the real economy is huge, there is no doubt about this
.
But at present, we can only be ourselves.
On the one hand, we must be mentally prepared for the epidemic.
On the other hand, we must be clear that opening up does not mean lying flat, and the country will still try to reduce the outbreak and impact of the epidemic
.
As an investor, I still recommend that all startups should not be overly enthusiastic about medical investment at this stage, and must first ensure that they have a certain amount of funds to survive the current cold winter
.

 

leave a message here